Kookmin Bio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $2.45M

  • Investors
  • 6

Kookmin Bio General Information

Description

Developer of microbiome-regulating materials and new drugs intended for preventive medicines. The company secures differentiated strain development, fermentation production technology, and core processes centering on the commercialization of biopharmaceutical materials that resolve the imbalance of the intestinal microflora, enabling patients to put life and health first.

Contact Information

Website
www.kmbio.co.kr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 116, Main Building, Jeonju National University
  • 303 Cheonjam-ro, Wansan-gu
  • Jeonju, Jeollabuk
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • Room 116, Main Building, Jeonju National University
  • 303 Cheonjam-ro, Wansan-gu
  • Jeonju, Jeollabuk
  • South Korea
+82

Kookmin Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kookmin Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 20-Nov-2024 $2.45M Completed Generating Revenue
4. Early Stage VC (Series A) 26-Oct-2023 Completed Generating Revenue
3. Accelerator/Incubator 21-Apr-2022 Completed Generating Revenue
2. Early Stage VC 18-Nov-2021 Completed Generating Revenue
1. Seed Round 22-Jan-2019 Completed Generating Revenue
To view Kookmin Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Kookmin Bio Patents

Kookmin Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026110978-A1 Composition for regulating and improving blood glucose Pending 22-Nov-2024

Kookmin Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kookmin Bio Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Industrial Bank of Korea PE/Buyout Minority
KGROUND Ventures Venture Capital Minority
Kookmin University Technology Holdings Venture Capital Minority
Korea Alternative Investment Corporation Asset Manager Minority
Tech Incubator Program for Startup Accelerator/Incubator
You’re viewing 5 of 6 investors. Get the full list »

Kookmin Bio FAQs

  • When was Kookmin Bio founded?

    Kookmin Bio was founded in 2019.

  • Where is Kookmin Bio headquartered?

    Kookmin Bio is headquartered in Jeonju, South Korea.

  • What is the size of Kookmin Bio?

    Kookmin Bio has 13 total employees.

  • What industry is Kookmin Bio in?

    Kookmin Bio’s primary industry is Drug Discovery.

  • Is Kookmin Bio a private or public company?

    Kookmin Bio is a Private company.

  • What is Kookmin Bio’s current revenue?

    The current revenue for Kookmin Bio is .

  • How much funding has Kookmin Bio raised over time?

    Kookmin Bio has raised $4.03M.

  • Who are Kookmin Bio’s investors?

    Industrial Bank of Korea, KGROUND Ventures, Kookmin University Technology Holdings, Korea Alternative Investment Corporation, and Tech Incubator Program for Startup are 5 of 6 investors who have invested in Kookmin Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process